Results 81 to 90 of about 121,431 (264)

Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor

Advanced Science, EarlyView.
The study characterizes C36, a highly selective EZH2/PRC2 inhibitor that acts via a novel allosteric mechanism. Unlike previous inhibitors, C36 inhibits EZH2/PRC2 by disrupting the allosteric communication between EZH2 and EED in a SAM‐noncompetitive manner.
Ting Cao, Dongdong Liu, Haishan Gao, Chenyang Qin, Wen Zhang, Ziyun Lu, Dongxia Tan, Yuxiu Qu, Yusong Liu, Zhiran Zou, Hongtao Yu, Wei Qi   +11 more
wiley   +1 more source

Intrinsically Mitochondria‐Targeting Nanozyme via Coordination‐Assembly of Natural Quercetin for Cascade Antioxidant Therapy of Cerebral Ischemia‐Reperfusion Injury

Advanced Science, EarlyView.
This study uncovers that quercetin naturally targets mitochondria. By coordinating quercetin with Fe3+, we engineer an ultrasmall cascade nanozyme (MCN) with superoxide dismutase‐catalase activities. MCN crosses the damaged blood–brain barrier, scavenges mitochondrial ROS, prevents mitochondrial DNA leakage, and blocks the cGAS‐STING pathway, thereby ...
Wenxuan Zheng, Zhicheng Wang, Xin Zhou, Shuya Wang, Xiaojing Shi, Tingli Xiong, Ruishi Li, Yuting Lin, Zhen Chen, Jiawen Wei, Fei Li, Jinwen Ge, Kelong Ai, Chong Liu, Guiming Deng   +14 more
wiley   +1 more source

Endobody: Genetically Encodable Nanobody‐CPP Chimeras for Degradation of Membrane and Extracellular Proteins

Advanced Science, EarlyView.
We introduced genetically encodable, receptor‐independent nanobody‐CPP chimeras, termed endobodies, as robust and modular membrane protein degraders. Additionally, proteasome‐targeting domain (PTD)‐tethered endobody demonstrates further enhanced degradation potency.
Chengjian Zhou, Huiping He, Simin Xia, Xi Chen   +3 more
wiley   +1 more source

Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity

Advanced Science, EarlyView.
Systemic and intramuscular delivery of autoantigen mRNA via lipid nanoparticles reprograms antigen‐presenting cells toward a mature, homeostatic state, driving antigen‐specific T cell exhaustion and providing therapeutic efficacy across autoimmune disease models.
Paulien Baeten, Karen Beets, Tessa Schalley, Janne Verreycken, Gayel Duran, Daphne Lintsen, Lisa Schuetz, Xue Zhong, Rinke Nieuwschepen, Melissa Schepers, Brecht Moonen, Jeroen Bogie, Jana Van Broeckhoven, Carlo Heirman, Jurgen Van den Heuvel, Bart Vanderborght, Ismael Varela, Roxanne Nouille, Lotte Jacobs, Jessica Filtjens, Sabah Kasmi, Elise Seynaeve, Veronica Mavrovouna, Jana De Vrieze, Michael A. Brehm, Sandra Maréchal, Sophie Janssens, Florence Lambolez, Niels Hellings, Stefaan De Koker, Bieke Broux   +30 more
wiley   +1 more source

Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment

Frontiers in Immunology, 2017
Primary human natural killer (NK) cells recognize and subsequently eliminate virus infected cells, tumor cells, or other aberrant cells. However, cancer cells are able to develop tumor immune escape mechanisms to undermine this immune control.
Olaf Oberschmidt, Stephan Kloess, Ulrike Koehl   +2 more
doaj   +1 more source

Artificial Host‐Guest Recognition Directs Glycometabolically Engineered Macrophages to Tumors

Advanced Science, EarlyView.
Glycoengineered supramolecular macrophages (GSAR‐M) are developed using glycometabolic labeling for bioorthogonal host‐guest tumor targeting. This engineering approach unexpectedly enhances macrophage migration, phagocytosis, and pseudopodia formation. Consequently, GSAR‐M demonstrate robust tumor‐targeting specificity, effectively arrest tumor growth,
Zhiqing Yang, Qian Cheng, Ziyi Wang, Jianwen Wei, Qun Guan, Huazhong Yu, Qingwen Zhang, Caixia Yin, Ruibing Wang   +8 more
wiley   +1 more source

Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response

Nature Communications, 2019
Supraphysiological T cell activation by chimeric antigen receptor (CAR) contributes to T cell exhaustion and adverse events in CAR T cell therapies. Here the authors engineer a synthetic antigen receptor that integrates into the endogenous TCR complex ...
Patrick A. Baeuerle, Jian Ding, Ekta Patel, Niko Thorausch, Holly Horton, Jessica Gierut, Irene Scarfo, Rashmi Choudhary, Olga Kiner, Janani Krishnamurthy, Bonnie Le, Anna Morath, G. Christian Baldeviano, Justin Quinn, Patrick Tavares, Qi Wei, Solly Weiler, Marcela V. Maus, Daniel Getts, Wolfgang W. Schamel, Robert Hofmeister   +20 more
doaj   +1 more source

A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma

Advanced Science, EarlyView.
A double‐layered shell‐core microneedle patch is developed to co‐deliver FOLFIRINOX, surufatinib, and anti‐PD‐1 for localized chemo‐immunotherapy of PDAC. This strategy achieves sustained tumor suppression, reduces metastasis, and reprograms the TME by enhancing CD8+ T‐cell infiltration and inhibiting Tregs and M2 macrophages infiltration, while ...
Tingting Kong, Ximo Xu, Xiao Zhang, Chuntao Wu, Zhengjun Qiu, Beiyuan Hu, Zihao Qi, Qiang Tian, Yuqin Yang, Hanguang Dong, Fei Wu, Tuo Jin, Yan Zheng, Jiang Long   +13 more
wiley   +1 more source

Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment

Advanced Science, EarlyView.
This study introduces an innovative strategy for the tumor‐selective catalytic degradation of oncogenic non‐coding RNA by interfacing a ribonuclease‐recruiting small molecule (RIBOTAC) with an EGFR‐targeting nanobody via a CTSB (Cathepsin B)‐responsive linker.
Tianli Luo, Yijuan Wang, Dengwang Chen, Yinghan Zhang, Yi Shuai, Hualiang Yao, Tao Jiang, Hang Jiang, Ming Zhong, Xiangeng Wang, Ziwei Wang, Chenchen Xu, Ajay Goel, Hoi Tang MA, Feng Gao, Xin Wang   +15 more
wiley   +1 more source

Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report

Journal of Medical Case Reports
Background Mantle cell lymphoma is a diverse B-cell lymphoma with varying clinical behaviors. Treating relapsed or refractory mantle cell lymphoma is challenging, with Bruton’s tyrosine kinase inhibitors proving effective but not curative.
G. Menardi, A. Castellino, C. Castellino, M. E. Bersia, E. Grande, G. Fraternali, M. Massaia, C. Fruttero   +7 more
doaj   +1 more source